TrovaGene, Inc. (NASDAQ:TROV) has been assigned a $4.00 price target by Maxim Group in a research report issued on Wednesday. The brokerage currently has a “buy” rating on the medical research company’s stock. Maxim Group’s price target points to a potential upside of 376.19% from the company’s previous close.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TrovaGene in a research report on Tuesday, August 8th.

TrovaGene (NASDAQ TROV) traded up 5.00% during trading on Wednesday, hitting $0.84. 768,163 shares of the stock were exchanged. The firm’s market capitalization is $31.31 million. TrovaGene has a 12-month low of $0.61 and a 12-month high of $5.98. The stock has a 50 day moving average price of $1.02 and a 200-day moving average price of $1.19.

COPYRIGHT VIOLATION WARNING: “Maxim Group Analysts Give TrovaGene, Inc. (TROV) a $4.00 Price Target” was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/08/16/maxim-group-analysts-give-trovagene-inc-trov-a-4-00-price-target-2.html.

A number of large investors have recently bought and sold shares of TROV. Goldman Sachs Group Inc. boosted its stake in TrovaGene by 1,079.5% in the second quarter. Goldman Sachs Group Inc. now owns 278,186 shares of the medical research company’s stock valued at $351,000 after buying an additional 254,601 shares in the last quarter. KCG Holdings Inc. boosted its stake in TrovaGene by 560.1% in the first quarter. KCG Holdings Inc. now owns 210,301 shares of the medical research company’s stock valued at $242,000 after buying an additional 178,440 shares in the last quarter. Susquehanna International Group LLP boosted its stake in TrovaGene by 2,781.0% in the second quarter. Susquehanna International Group LLP now owns 138,031 shares of the medical research company’s stock valued at $174,000 after buying an additional 133,240 shares in the last quarter. Two Sigma Securities LLC boosted its stake in TrovaGene by 262.4% in the first quarter. Two Sigma Securities LLC now owns 120,516 shares of the medical research company’s stock valued at $139,000 after buying an additional 87,264 shares in the last quarter. Finally, LMR Partners LLP bought a new stake in TrovaGene during the second quarter valued at approximately $151,000. 15.14% of the stock is currently owned by institutional investors and hedge funds.

About TrovaGene

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.